What is Brief History of Organon Company?

How did Organon become a global women's health leader?

Organon began in 1923 in Oss, Netherlands, extracting medicinal value from animal glands and later focused on endocrine research. Its 1962 launch of Lyndiol marked a breakthrough in reproductive medicine, shaping its long-term role in women’s health.

Organon spun off from Merck in 2021 and by 2025 reported annual revenues near $6.5 billion, operating in over 140 markets with a portfolio across women's health, biosimilars, and established brands. Read more analysis: Organon Porter's Five Forces Analysis

Organon was founded on June 29, 1923, in Oss, Netherlands, to convert animal by-products into therapeutic hormones; its early focus on organ-derived endocrine treatments set the foundation for rapid pharmaceutical growth.

Founding Story

Dr. Saal van Zwanenberg launched Organon in 1923, leveraging Zwanenberg meat-packing resources and scientific partners to produce organ-derived hormones such as insulin.

• Founded on June 29, 1923 in Oss, Netherlands
• Founded by Dr. Saal van Zwanenberg using internal funding from the meat-packing business
• Collaborated with pharmacologist Ernst Laqueur from the University of Amsterdam
• First major product: production of insulin in 1924, the first European manufacturer to commercialize it

Van Zwanenberg’s vertical integration—linking meat-packing supply chains to chemical processing—enabled Organon company founding to bypass external seed rounds and scale production capacity quickly, addressing early supply chain constraints other startups faced in the 1920s.

The name Organon comes from Greek for instrument or organ, reflecting Organon pharmaceutical origins and the company’s emphasis on organ-derived hormones; this stage appears as a key entry in the Organon company timeline and the broader History of Organon.

By converting animal organs and glands (notably pancreas tissue) into hormone products, Organon’s early years combined industrial processing with academic endocrinology, establishing key milestones in Organon history and a business model that supported subsequent expansion into endocrine therapeutics.

For more on the company’s guiding principles and later evolution, see Mission, Vision & Core Values of Organon

Complete Organon Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

During the 1930s–1940s Organon company history accelerated beyond the Netherlands, shifting from general endocrine products to specialized sex hormones and establishing European operations that set the stage for postwar expansion.

International expansion

By the late 1930s Organon had active operations in the United Kingdom and multiple European markets, marking early chapters in the Organon company timeline.

Product specialization

The firm transitioned to sex-hormone therapeutics, launching Menformon—one of the first standardized estrogen products—anchoring its reputation in gynecological health.

Postwar consolidation

After World War II Organon merged with Zwanenberg to form Zwanenberg-Organon, a key milestone in Organon company history that preceded the 1970 merger creating Akzo; these moves expanded capital and industrial reach.

Contraceptive leadership

The 1962 launch of Lyndiol propelled Organon into the global contraceptive market; subsequent products like NuvaRing and Implanon later became central to its blockbuster portfolio.

Through the 1970s–1980s Organon expanded R&D sites in the United States and Asia and shifted strategic focus from manufacturing to research-driven development, laying groundwork that by 2007 supported its acquisition by Schering-Plough for approximately €11 billion.

Further details and a broader Organon company timeline are available in this article: Brief History of Organon

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Milestones, Innovations and Challenges trace Organon company history from its early pharmaceutical origins through key milestones, pioneering long-acting contraceptives and a 2021 spin-off that refocused capital toward women’s health and biosimilars amid structural and financial headwinds.

Organon strengthened its innovation pipeline by combining pharmacology and devices, notably integrating the Jada System to address postpartum hemorrhage. The company also scaled biosimilars like Hadlima to offset loss of exclusivity for legacy brands.

Nexplanon — LARC leadership

Nexplanon remained a portfolio cornerstone with near-$900,000,000 in annual sales by 2025, anchoring Organon’s women’s health revenue.

Spin-off refocus

The June 3, 2021 spin-off restored capital allocation discipline toward women’s health and biosimilars after years under Merck’s broader priorities.

Device acquisition — Jada System

The 2024 acquisition of Alydia Health signaled a strategic shift into devices addressing postpartum hemorrhage, a leading cause of maternal mortality.

Biosimilars expansion

Launch and scale of Hadlima (biosimilar to Humira) became a priority to counteract branded revenue erosion and patent cliffs.

Commercial reorientation

Post-spin-off, Organon reallocated R&D and commercial spend toward niche women's health indications to build a defensive moat.

Financial restructuring

Management pursued debt reduction and cash-flow improvements to address a high debt-to-EBITDA ratio inherited from the spin-off.

Challenges included navigating a high debt-to-EBITDA ratio after the spin-off and managing multiple brand patent expirations that pressured top-line growth in 2024–2025. Leadership responded by prioritizing biosimilars, devices and targeted women’s health investments to stabilize revenue and margin profiles.

Legacy integration under Merck

Under Merck from 2009, Organon company history shows women’s health programs received limited capital as oncology and vaccines dominated corporate priorities, delaying focused investment.

Debt burden

Post-spin-off leverage resulted in a high debt-to-EBITDA ratio that constrained near-term M&A and R&D freedom until deleveraging progressed.

Loss of exclusivity

Multiple brands faced loss of exclusivity through 2024–2025, forcing a strategic pivot to biosimilars and new product categories to preserve revenue.

Commercial competition

Competing with larger, diversified pharmaceutical rivals required Organon to create a niche moat via focused women’s health offerings and device integration.

Regulatory pathways for biosimilars

Scaling biosimilars like Hadlima demanded significant regulatory and market-access efforts to secure formulary placement and uptake.

Market positioning

Building brand equity after the spin-off required focused marketing and clinical evidence generation to regain share in core women’s health segments.

For additional context on competitive dynamics and how these milestones compare across peers, see Competitors Landscape of Organon

Organon Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Timeline and Future Outlook: a concise Organon company timeline traces its origins from 1923 in Oss to its 2021 NYSE spin‑off and highlights milestones through 2025, while outlining growth prospects across Women’s Health, Biosimilars and Established Brands.

Three‑Pillar Growth Strategy

Organon continues to prioritize Women’s Health, Biosimilars and Established Brands, leveraging a focused portfolio that targets underserved patient groups and sustainable revenue streams.

Women’s Health Forecast

Analysts expect the Women’s Health segment to grow at a mid‑single‑digit rate, supported by Nexplanon dominance and expanding fertility and menopause offerings.

Biosimilars Opportunity

Organon is investing heavily in biosimilars R&D and manufacturing to capture market share as biologic patents expire; Hadlima’s US launch in 2023 exemplifies this push.

Capital Allocation & M&A

Leadership intends to use free cash flow for bolt‑on acquisitions in menopause, maternal health and endometriosis to accelerate pipeline and address unmet needs.

Marketing Strategy of Organon

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE